Estimating the 'Deep-Replicability' of scientific findings

AI speeds up search for COVID-19 treatments and vaccines

Researchers at Northwestern University are using artificial intelligence (AI) to speed up the search for COVID-19 treatments and vaccines. The AI-powered tool makes it possible to prioritize resources for the most promising studies — and ignore research that is unlikely to yield benefits.

Image source: Shutterstock/Lightspring

In the midst of the pandemic, scientific research is being conducted at an unprecedented rate. The Food and Drug Administration (FDA) and the U.S. Department of Health and Human Services announced plans to accelerate clinical trials, and hundreds of scientists are investigating possible treatments and vaccines. But the question remains: Which research has the most potential to produce real, much-needed solutions?

The standard process is too expensive, both financially and in terms of opportunity costs

Brian Uzzi

The scientific community has been predicting the answer to such questions for decades using the Defense Advanced Research Projects Agency’s Systematizing Confidence in Open Research and Evidence (DARPA SCORE) program. The program relies on scientific experts to review and rate submitted research studies based on how likely they are to be replicable. On average, this process takes about 314 days – a long wait in the midst of global pandemic.

The machine model is just as accurate as the human scoring system at making such predictions, researchers said, and it can scale up to review a larger number of papers in a fraction of the time – minutes instead of months. “The standard process is too expensive, both financially and in terms of opportunity costs,” said Northwestern’s Brian Uzzi, who led the study. “First, it takes take too long to move on to the second phase of testing and second, when experts are spending their time reviewing other people’s work, it means they are not in the lab conducting their own research.”

With their new AI tool, Uzzi and his team at the Kellogg School of Management bypass the human-scoring method, allowing the research community and policymakers to make faster decisions about how to prioritize time and funding on the studies that are most likely to succeed.

portrait of brian uzzi
Brian Uzzi is the Richard L. Thomas Professor of Leadership at Kellogg and co-director of the Northwestern Institute on Complex Systems
Source: Northwestern University

Uzzi is the corresponding author on the paper, titled “Estimating the 'Deep-Replicability' of Scientific Findings Using Human and Machine Intelligence,” which will be published the week of May 4 in PNAS. “In the midst of a public health crisis, it is essential that we focus our efforts on the most promising research,” said Uzzi, the Richard L. Thomas Professor of Leadership at Kellogg and co-director of the Northwestern Institute on Complex Systems. “This is important not only to save lives, but also to quickly tamp down the misinformation that results from poorly conducted research.”

The team of Northwestern researchers developed an algorithm to predict which studies’ results are most likely to be replicable. Replication, which means that the results of the study can be produced a second time with a new test population, is a key signal that study conclusions are valid. The machine model’s prediction of the likelihood of replicability may actually be more accurate than the traditional human-scoring prediction, researchers said, because it considers more of the narrative of the study, while expert reviewers tend to focus on the strength of the relational statistics in a paper. “There is a lot of valuable information in how study authors explain their results,” Uzzi said. “The words they use reveal their own confidence in their findings, but it is hard for the average human to detect that.”

Because the algorithm examines the words of thousands of papers, it recognizes word-choice patterns that might be hidden from human consciousness. It has a much bigger schema to draw upon for its predictions, which makes it an extraordinary partner for human reviewers, Uzzi said.

The researchers’ model can be used immediately to analyze COVID-related research papers and quickly determine which show the most promise. “This tool is particularly useful in this crisis situation where we can’t act fast enough,” Uzzi said. “It can give us an accurate estimate of what’s going to work and not work very quickly. We’re behind the ball, and this can help us catch up.”

Used on its own, the model has comparable accuracy to the DARPA SCORE method. Paired together, the combination human-machine approach predicts which findings will be replicable with even greater accuracy than either method on its own, the researchers found. “This tool will help us conduct the business of science with greater accuracy and efficiency,” Uzzi said. “Now more than ever, it’s essential for the research community to operate lean, focusing only on those studies which hold real promise.”


Source: Northwestern University

05.05.2020

Read all latest stories

Related articles

Photo

From physical to computational staining

Deep learning accurately stains digital biopsy H&E slides

Tissue biopsy slides stained using hematoxylin and eosin (H&E) dyes are a cornerstone of histopathology, especially for pathologists needing to diagnose and determine the stage of cancers. A…

Photo

Profiling the coronavirus

Risk factors for severe and fatal COVID-19 cases identified

Age, male sex, obesity, and underlying illness have emerged as risk factors for severe and fatal cases of COVID-19 in the UK, according to the largest cohort study to date published by The BMJ. As…

Photo

Canine vs. coronavirus

Trained dogs can detect COVID-19 with their nose

The extremely sensitive olfactory sense of dogs might prove to become a groundbreaking new tool in the fight against the COVID-19. Trained medical scent detection dogs have previously worked with…

Related products

Eppendorf – Mastercycler nexus X2

Research Use Only (RUO)

Eppendorf – Mastercycler nexus X2

Eppendorf AG
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH